Compare Becton Dickinson and Co (BDX) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs IONQ Inc — how do they compare? Becton Dickinson and Co trades at $156.52 (market cap $41.51B), while IONQ Inc trades at $37.78 (market cap $14.67B). The key difference: Becton Dickinson and Co is far larger — about 2.8× IONQ Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| BDX | IONQ | |
|---|---|---|
Market Cap | $41.51B | $14.67B |
Sector | Health | Technology |
52-Week High | $185.39 | $82.09 |
52-Week Low | $135.49 | $26.59 |
Enterprise Value | $57.97B | $12.66B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
IONQ shares declined 9.29% to $38.88 amid broader quantum computing sector weakness, though technical indicators show oversold conditions with RSI at 16.05. The company maintains a mixed fundamental picture with strong revenue growth projections ($130M in 2025 to $187M in 2026) but significant operating losses. Analyst sentiment remains divided with a 50/50 buy/hold split despite a consensus price target of $73.75 representing 90% upside potential from current levels.
The stock presents high-risk, high-reward potential with Wall Street recognizing IONQ's leadership in trapped-ion quantum computing technology but concerned about cash burn and execution risks. Near-term catalysts include Q2 2026 earnings and the planned 256-qubit system demonstration, though the stock faces volatility from speculative trading and competitive pressures in the emerging quantum sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
